OS Therapies (OSTX) Times Interest Earned (2023 - 2026)

OS Therapies' (OSTX) quarterly Times Interest Earned came in at -$66.2 in Q1 2026, down 713.42% on a QoQ basis from -$8.14 in Q4 2025.

OS Therapies (OSTX) Times Interest Earned (2023 - 2026) Analysis & Trends

OS Therapies (OSTX) has 4 years of Times Interest Earned data on file, last reported at -$66.2 in Q1 2026.

Quarterly Times Interest Earned changed N/A year-over-year to -$66.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.73 (down 126.71% YoY) and the FY2025 annual result came in at -$19.49, down 2331.4% from the prior year.
Times Interest Earned fell to -$66.2 in Q1 2026, from -$8.14 in the prior quarter.
In the past five years, Times Interest Earned ranged from a high of -$0.46 in Q3 2023 to a low of -$392.59 in Q4 2024.
A 4-year average of -$42.15 and a median of -$4.66 in 2023 frame the typical range for Times Interest Earned.
Annual changes were most pronounced in 2024 — Times Interest Earned slumped 10334.92% — and 2025, when it surged 97.93%.
Tracing OSTX's Times Interest Earned over 4 years: stood at -$3.76 in 2023, then tumbled by 10334.92% to -$392.59 in 2024, then surged by 97.93% to -$8.14 in 2025, then sank by 713.42% to -$66.2 in 2026.
The last three Times Interest Earned figures came in at -$66.2 (Q1 2026), -$8.14 (Q4 2025), and -$13.84 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	117.59
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	8.18
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	2.82
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	76.86
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.08
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	1.42
10	OS Therapies	19.46 Mn	19.46 Mn	-	-167.36

Download Data